Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office							Atty. Docket No. A35478 066123.0125 Applicant Tyagi et al. Serial No. 10/687,402				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					TEMENT						
(Use several sheets if necessary)						y)	Filing Date Group October 16, 2003 1651				
DEC 0 8 2004	FICE			,							
CENTER OF THE PERSON NAMED IN	/					U.S. PATEN	T DOCUMENTS				
Exam. Init.		cumen		La	1 2	Date	Name	Class	Subclass	Filing I	
SA N	5 1 6	2	6	2	7	12/19/2000	Inouye et al.	435	194		····
				·	FO	REIGN PA	TENT DOCUMENT			J	
		cumen	No.			Date	Country	Class	SubClass	Transla Yes	
SJ 0 3	0 6	6	8	3	8	08/14/2003	WIPO		<u> </u>		
<i>SS</i> ,	Anderso inferred a mycol Armitig 85B of 78 Baikalo Structur Baltch, postanti Enteroc Barrett, therapy. Barry, C the deve	on D.H from the yl transe, L.Y. Mycobo v, I., See of the A.L., See of the Diocice of the J.F. and Antin	chrod e Esciund Honicrob	th G., ystal e. J. Innath um tu er, I., s of L. R.P., ch. J. Ch., J. C	Horving Struct Mol. 1, C., the Constitution of	witz M.A. and bures of the Myc Biol. 307, 677 Wanger, A.R. adosis H37Rv: Extra Grant Francisco of the Myc Biol. 307, 677 Wanger, A.R. adosis H37Rv: Extra Grant Francisco of the Myc Biol. 328 and Ampic Crob. Agents Company Two-components of the Myc Biol. 42, Simpson, A.E. cobacterial drugs of the Myc Biol. 307, 677 Wanger Simpson, A.E. cobacterial drugs of the Myc Biol. 307, 677 Wanger Simpson, A.E. cobacterial drugs of the Myc Biol. 307, 677 Wanger Simpson, A.E. cobacterial drugs of the Myc Biol. 307, 677 Wanger Simpson, A.E. cobacterial drugs of the Myc Biol. 307, 677 Wanger, A.R. was also with the Myc Biol. 307, 677 Wanger, A.R. was also with the Myc Biol. 307, 677 Wanger, A.R. was also with the Myc Biol. 307, 677 Wanger, A.R. was also with the Myc Biol. 307, 677 Wanger, A.R. was also with the Myc Biol. 307, 677 Wanger, A.R. was also with the Myc Biol. 307, 677 Wanger, A.R. was also with the Myc Wanger, A.R. wa	and Norris, S.J. (2000) Disruptifiect on growth in culture and ak, M., Grzeskowiak, K., Gurallator NarL. <i>Biochemistry</i> 35, p., L.H. (1998) Comparison of illin used singly and in combinemother. 42, 2564-2568 uponent signal transduction as	facial mechanical major secretion of gene ed in macrophages as alus, R.P. ar 11053 - 1106 finhibitory and mation against a target for magenomics and p, 221-231	ism and a clietory protein moding ant ges. Infect. Ind Dickerson l d bactericida vancomycinicrobial anti	igen 85A Immun. n, R.E. (al activiti n – resist in infecti	and 68, 76 1996) es and ant ve
JY02:505269.1						2 – 2676	1		•		

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Fe 1	TO 1440	II & Danastmant of Commerce	Atty. Docket No.	Serial No.		
		U.S. Department of Commerce tent and Trademark Office	A35478 066123.0125	10/687,402		
INF	ORMAT	TION DISCLOSURE STATEMENT BY APPLICANT	Applicant Tyagi et al.			
	(Use	e several sheets if necessary)	Filing Date October 16, 2003	Group 1651		
St		Bradford, M. M. (1976) A rapid and sensitiv the principle of protein – dye binding. <i>Anal.</i>		icrogram quantities of protein utilizin		
		Chen, P., Ruiz, R.E., Li, Q., Silver, R.F. and tuberculosis mutant lacking the alternate sign				
		Cole et al. (1998) Deciphering the biology of Nature 393, 537 – 544	Mycobacterium tuberculosis from	n the complete genome sequence.		
		Collins D.M., Kawakami R.P., de Lisle G.W., Pascopella L., Bloom B.R. and Jacobs W.R. Jr. (1995) Mutation the principal sigma factor causes loss of virulence in a strain of the <i>Mycobacterium tuberculosis</i> complex. Proc. Acad. Sci. USA 92, 8036 - 8040				
		Cooper J.B., McIntyre K., Badasso M.O., Wo analysis of the iron-dependent superoxide distreveals novel dimer-dimer interactions. J. Mo	mutase from Mycobacterium tuber			
-		Cox J.S., Chen B., McNeil M. and Jacobs W. Mycobacterium tuberculosis in mice, Nature 4		rmines tissue-specific replication of		
		Dasgupta, N., Kapur, V., Singh, K.K., Das, T. of a two-component system, devR-devS, of My				
		DeMaio J., Zhang Y., Ko C., Young D.B. and from Mycobacterium tuberculosis. Proc. Nat				
		Denis et al. (1999) Synthesis and antibacteria erthryomycin – resistant and susceptible patho				
		Deschenes, R.J., Lin, H., Ault, A.D. and Fass putative bacterial histidine kinase inhibitors.				
		Domagala, J.M., Alessi, D., Cummings, M., e in drug design: Inhibition of NRII by dipheno				
		Doukhan, L., Predich, M., Nair, G., Dussurger Genomic organization of the mycobacterial si				

NY02:505269.1

2

Examiner

Date Considered

12-20-04

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

REV. 2-82) Patent and Trademark Office			A35478 066123.0125 Applicant	10/687,402			
INFO	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Tyagi et al.				
	(Use	several sheets if necessary)	Filing Date October 16, 2003	Group 1651			
4		Dziejman, M. and Mekalanos, J.J. (1995) two bacterial virulence factors in Hock, J.A. and S DC. American Society for Microbiology. Pp.	Silhavy, T.J. Eds. Two componer				
		El-Masry, A.H., Fahony, H.H. and Abdelwahed, S.H.A. (2000) Synthesis and anti microbial activity of some ne benzimidazole derivatives. <i>Molecules</i> 5, 1429 – 1438					
		Frechette, R.F., Beach, M.J., Bernstein, J. et a bacterial two-component signal transduction s Meeting, Las Vegas, NV, USA					
		Glickman, M.S., Cox, J.S. and Jacobs, W.R. coding, persistence and virulence of <i>Mycobaci</i>					
		Grange, J.M. (1992) The mystery of the mycobacterial 'persistor'. Tuber. Lung Dis. 73, 249 - 251					
		Haydel, S.E., Dunlap, N.E. and Benjamin, W. phosphorylation between the <i>Mycobacterium</i> in					
		Himpens, S., Locht, C. and Supply, P. (2000) component system: evidence for autoregulatio		e mycobacterial SenX3 – RegX3 two-			
		Jackson, M., Crick, D.C. and Brennan, P.J. (2 J. Biol. Chem. 275, 30092 - 30099	2000) Phosphatidylinositol is an e	ssential phospholipid of mycobacteria			
		Kinger, A.K. and Tyagi, J.S. (1993) Identific of Mycobacterium tuberculosis. Gene 131, 11		ntially expressed in the virulent strair			
		Klimesova, V., Koc, J., Pour, M., Stachel, J., Vevaluation of benzimidazole derivatives as ant					
		Klimesova, V., Koc, J., Waisser, K. and Kaus agents. Il Farmaco, 57, 259 – 265	tova, J. (2002b) New benzimidaz	zole derivatives as antimycobacterial			
		Kramer MI and Grunhera E (1973) Effect of	f ethidium bromide against transc	plantable tumors in mice and rats.			

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

12-20-04

Examiner

	•				
Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office			Atty. Docket No. A35478 066123.0125	Serial No. 10/687,402	
INFO	ORMAT	TION DISCLOSURE STATEMENT BY APPLICANT	Applicant Tyagi et al.		
	(Use	e several sheets if necessary)	Filing Date October 16, 2003	Group 1651	
•			1		
J.J.		Phetsuksiri, B., Baulard, A.R., Cooper, A.M., Antimycobacterial activities of isoxyl and new Antimicrob. Chemother. 43, 1042-1051			
1		Li, Z., Kelley, C., Collins, F., Rouse, D. and Massociated with its growth and persistence in n			
-		Macielag, M.J. and Goldschmidt, R. (2000) I Invest. Drugs 9, 2351 – 2369	nhibitors of bacterial two-compor	nent signalling system. Exp. Opin.	
		Manganelli, R., Voskuil, M.I., Schoolnik, G.K factor sigmaE: role in global gene expression			
		Matsushita, M. and Janda, K.D. (2002) Histic Chem. 10, 855 – 867	dine kinases as targets for new and	rimicrobial agents. Bioor. Med.	
•		Mayuri, Bagchi, G., Das, T.K. and Tyagi, J.S. Mycobacterium smegmatis. Expression analyst Rv3134c and chaperone – crystalline homolog	sis of the genes encoding DevR -	DevS two-component system,	
		McKinney, J.D., Bentrup, K.H., Munoz-Elias, Jacobs, W.R. Jr. and Russell, D.G (2000) P glyoxylate shunt enzyme isocitrate lyase. <i>Nat</i>	ersistence of M. tuberculosis in m		
		Mitchison, D.A. (1998) How drug resistance of tuberculosis. Int. J. Tuberc. Lung Dis. 2, 10		iance during short – chemotherapy for	
		Mukamolova G.V., Kaprelyants A.S., Young Acad. Sci. USA. 95, 8916 - 8921	D.I., Young M. and Kell D.B. (1	998) A bacterial cytokine. Proc. Nat	
		Parkinson, J.S. and Kofoid, E.C. (1992) Com 26, 71 – 112	nmunication modules in bacterial s	signalling proteins. Ann. Rev. Genet.	
		Parrish, N., Dick, J.D. and Bishai, W.R. (199 <i>Microbiol</i> . 6: 107-112	8) Mechanisms of latency in <i>Myc</i>	obacterium tuberculosis. Trends	

NY02:505269.1

Examiner Land

Date Considered

4

Perez, E., Samper, S., Bordas, Y., Guilhot, C., Gicquel, B. and Martin, C. (2001) An essential role for phoP in

12-20-04

Mycobacterium tuberculosis virulence. Mol. Micro. 41, 179 - 87

Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) Pohl, E., Holmes, R.K. and Hol, W.G. (1999) Crystal structure of the iron-dependent regulator (IdeR) from Mycobacterium tuberculosis shows both metal binding sites fully occupied. J. Mol. Biol. 285, 1145 - 1156

		Raman, S., Song, T., Puyang, X., Bardarov, S., Jacobs, W.R. Jr. and Husson, R.N. (2001) The alternative sigma factor SigH regulates major components of oxidative and heat stress responses in <i>Mycobacterium tuberculosis</i> . J. Bacteriol. 183, 6119 - 6125 Ronning, D.R., Klabunde, T., Besra, G.S., Vissa, V.D., Belisle, J.T. and Sacchettini, J.C. (2000) Crystal structure of
		the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat. Struct. Biol. 7 141 - 146
		Roychoudhary, S., Zielinski, N.A., Ninfa, A.J., Allen, N.E., Jungheim, L.N., Nicas, T.I. and Chakrabarty, A.M. (1993) Inhibitors of two-component signal transduction systems: Inhibition of alginate gene activation in <i>Pseudomonas aerugin osa. Proc. Natl. Acad. Sci. USA.</i> 90, 965 – 969
		Sherman, D.R., Voskuil, M., Schnappinger, D., Liao, R., Harrell, M.I. and Schoolnik, G.K. (2001) Regulation of the <i>Mycobacterium tuberculosis</i> hypoxia response gene encoding α-crystallin. <i>Proc. Natl. Acad. Sci. USA</i> 98, 7534 – 7539
		Stead, W.W. (1967) Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? <i>Am. Rev. Respir. Dis.</i> 95, 729 – 745
		Stead, W.W., Kerby, D.P., Schleuter, D.P. and Jordahl, C.W. (1968) The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. <i>Ann. Intern. Med.</i> 68, 731 – 745
		Stephenson, K., Yamaguchi, Y., Hoch, J.A. (2000) The mechanism of action of inhibitors of bacterial two-componen signal transduction systems. J. Biol. Chem. 275, 38900 - 38904.
		Stock, A.M., Robinson, V.L. and. Goudreau, P.N. (2000) Two-component signal transduction. Ann. Rev. Biochem 69, 183 – 215
		Stock, J.B., Surette, M.G., Levit, M. and Park, P. (1995) Two-component signal transduction systems: structure-function relationships and mechanisms of catalysis. In: Hock, J.A. and Silhavy, T.J. Eds. Two component signal transduction. Washington, DC. American Society for Microbiology. Pp. 25 – 51
		Stover, C.K., Warrener, P., VanDevanter, D.R., Sherman, D.R., Arain, T.M., Langhorne, M.H., Anderson, S.W., Towell, J.A., Yuan, Y., McMurray, D.N., Kreiswirth, B.E., Barry, C.E. III and Baker, W.R. (2000) A small molecul nitroimidaofuran drug candidate for treatment of tuberculosis. <i>Nature</i> 405, 962 - 66
		Strauch, M.A., De Mendoza, D. and Hoch, J.A. (1992) cis – Unsaturated fatty acids specifically inhibit a signal – transducing protein kinase required for initiation of sporulation in B. subtilis. Mol. Microbiol. 6, 2909 – 2917
NY02:505269.	1 .	5
Examiner	S	Date Considered 12-20-04

Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT **BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.	Serial No.	
A35478 066123.0125	10/687,402	
Amiliana		
Applicant Traci et al		

Tyagi et al.

Filing Date October 16, 2003 Group 1651

St.	Ulijasz, A.T. and Weisblum, B. (1999) Dissecting the VanRS signal transduction pathway with specific inhibitors. J Bacteriol. 181, 627 – 631
	Upton, A., Johnson, N., Sandy, J. and Sim, E. (2001) Arylamine N-acetyltransferases - of mice, men and microorganisms. <i>Trends Pharmacol</i> . Sci. 22, 140 - 146
	Urbanski, M.J., Xiang, M.A., Foleno, B.D. et al. (1997) Novel cyclohexene derivatives with histidine protein kinase inhibitory activity - potential new antibacterial agents. Abstract No. 270, Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, USA
	Wallis, N.G. (1999) Bacterial two-component signal transduction systems as drug targets. Curr. Opin. Anti-infect. Invest. Drugs. 1, 428 – 434
,	Weber, I., Fritz, C., Ruttkowski, S., Kreft, A. and Bange, FC. (2000) Anaerobic nitrate reductase (narGHJI) activit of Mybocaterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol. Microbiol. 35 1017 – 1025
,	West, M.L. and Fairlie, D.P. (1995) Targeting HIV-1 protease: a test of drug-design methodologies. <i>Trends Pharmacol</i> . Sci. 16, 67 - 94
	WHO report on the Global Tuberculosis Epidemic (1998) WHO Geneva
	Wilson T.M., de Lisle, G.W. and Collins, D.M. (1995) Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol. Microbiol. 15, 1009 - 1015
	Yuan, Y., Crane, D.C., Simpson, R.M., Zhu, Y.Q., Hickey, M.J., Sherman, D.R. and Barry, C.E. III. (1998) The 16 kDa a - crystalline (Acr) protein of <i>Mycobacterium tuberculosis</i> is required for growth in macrophages. <i>Proc. Natl. Acad. Sci.</i> USA 95, 9578 – 9583
	Zahrt, T.C. and Deretic, V., (2000) An essential two-component signal transduction system in <i>Mycobacterium tuberculosis</i> . J. Bacteriol. 182, 3832 – 3838
	Zahrt, T.C and Deretic, V. (2001) Mycobacterium tuberculosis signal transduction system required for persistent infection. Proc. Natl. Acad. Sci. (USA) 98, 12706 - 11
	Zhang, Y. and Amzel, L.M. (2002) Tuberculosis drug targets. Current Drug Targets 3, 131 - 154
Y02:505269.1	6
Examiner	Date Considered 12-20-04

Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.